Psychedelics and Mental Health: Hope, Hype, and the Road Ahead

As the FDA weighs the first federal approval of a psychedelic-assisted therapy, please join the Solomon Center for Health Law and Policy at Yale Law School for an expert panel on what psychedelic medicine could mean for mental health care, including the scientific, regulatory, and access questions that will shape its use.

Panelists:

Mary Giliberti ’92, Fmr. Chief Public Policy Officer, Mental Health AmericaDr. Nathaniel Mohatt, Program Manager, Proactive Health, Advanced Research Projects Agency for Health (ARPA-H)Dr. David B. Yaden, Roland Griffiths Professor of Psychedelic Research, Johns Hopkins University School of Medicine

Moderated by Dr. Mason Marks, MSU Research Foundation Distinguished Professor of Law, Michigan State University and former Project Lead of the Project on Psychedelics Law and Regulation at Harvard Law School.

Space is limited. RSVP required. There will be a wait list if demand is high. Non-pizza lunch will be provided.

This event is off the record and closed to press.